Endothelial function, endothelin-1, and fibrinogen in young women using the vaginal contraceptive ring

Fertility and Sterility

Volumn 92, Issue 2, 2009, Pages 441-447

  Torgrimson, Britta N ^a   Meendering, Jessica R ^a   Miller, Nicole P ^a   Kaplan, Paul F ^a,b   Minson, Christopher T ^a  

^a UNIVERSITY OF OREGON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Estradiol; estrogen; etonorgestrel; flow mediated dilation; hormonal contraception; hormone delivery; progestin; vascular health

Indexed keywords

CHOLESTEROL; CONTRACEPTIVE AGENT; ENDOTHELIN 1; ETHINYLESTRADIOL PLUS NORGESTREL; FIBRINOGEN; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DOPPLER FLOWMETRY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; VAGINA RING; VASODILATATION;

ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRACHIAL ARTERY; CONTRACEPTIVE DEVICES, FEMALE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HEART RATE; HUMANS; MENSTRUAL CYCLE; VASODILATION;

EID: 67651094069     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.06.054     Document Type: Article

References (54)

1. A preliminary communication to the Medical Research Council by a Subcommittee. Risk of thromboembolic disease in women taking oral contraceptives. Br Med J 2 (1967) 355-359
2. Daly E., Vessey M.P., Hawkins M.N., Carson J.L., Gough P., and Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
3. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., and Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
4. Mueck A.O., Seeger H., Petersen G., Schulte-Wintrop E., and Wallwiener D. Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. Contraception 64 (2001) 357-362
5. Mueck A.O., Seeger H., and Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 9 (2002) 273-281
6. Rickenlund A., Eriksson M.J., Schenck-Gustafsson K., and Hirschberg A.L. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrin Metab 90 (2005) 1354-1359
7. van Rooijen M., von Schoultz B., Silveira A., Hamsten A., and Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol 186 (2002) 44-48
8. Virdis A., Pinto S., Versari D., Salvetti G., Bernini G., Fruzzetti F., et al. Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens 21 (2003) 2275-2280
9. Elkind-Hirsch K.E., Darensbourg C., Ogden B., Ogden L.F., and Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 76 (2007) 348-356
10. Cid M.C., Schnaper H.W., and Kleinman H.K. Estrogens and the vascular endothelium. Ann N Y Acad Sci 966 (2002) 143-157
11. Farhat M.Y., Lavigne M.C., and Ramwell P.W. The vascular protective effects of estrogen. FASEB J 10 (1996) 615-624
12. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., and Cannon R.O. Acute vascular effects of estrogen in postmenopausal women. Circulation 90 (1994) 786-791
13. Mendelsohn M.E. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89 (2002) 12E-18E
14. Meendering J.R., Torgrimson B.N., Kaplan P.F., Miller N.P., and Minson C.T. Estrogen, medroxyprogesterone acetate, endothelial function and biomarkers of cardiovascular risk in young women. Am J Physiol 294 (2008) H1630-H1637
15. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273 (1995) 199-208
16. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., and Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325 (1991) 1196-1204
17. Torgrimson B.N., Meendering J.R., Kaplan P.F., and Minson C.T. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol. Am J Physiol 292 (2007) H2874-H2880
18. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
19. Doshi S.N., Naka K.K., Payne N., Jones C.J., Ashton M., Lewis M.J., et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci 101 (2001) 629-635
20. Rossi R., Nuzzo A., Origliani G., and Modena M. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 51 (2008) 997-1002
21. Griendling K.K., and Alexander R.W. Endothelial control of the cardiovascular system: recent advances. FASEB J 10 (1996) 283-292
22. Hasdai D., and Lerman A. The atherogenic potential of endothelin. Coron Artery Dis 6 (1995) 901-904
23. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., and Burnett Jr. J.C. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325 (1991) 997-1001
24. Lerman A., Holmes Jr. D.R., Bell M.R., Garratt K.N., Nishimura R.A., and Burnett Jr. J.C. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92 (1995) 2426-2431
25. Farmer R.D.T., Lawrenson R.A., Thompson C.R., Kennedy J.G., and Hambleton I.R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349 (1997) 83-88
26. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 312 (1996) 83-88
27. Gnasso A., Carallo C., Irace C., De Franceschi M.S., Mattioli P.L., Motti C., et al. Association between wall shear stress and flow-mediated vasodilation in healthy men. Atherosclerosis 156 (2001) 171-176
28. Betik A.C., Luckham V.B., and Hughson R.L. Flow-mediated dilation in human brachial artery after different circulatory occlusion conditions. Am J Physiol 286 (2004) H442-H448
29. Duffy S.J., New G., Tran B.T., Harper R.W., and Meredith I.T. Relative contribution of vasodilator prostanoids and NO to metabolic vasodilation in the human forearm. Am J Physiol 276 (1999) H663-H670
30. Pyke K.E., Dwyer E.M., and Tschakovsky M.E. Impact of controlling shear rate on flow-mediated dilation responses in the brachial artery of humans. J Appl Physiol 97 (2004) 499-508
31. Yashiro Y., and Ohhashi T. Flow- and agonist-mediated nitric oxide- and prostaglandin-dependent dilation in spinal arteries. Am J Physiol 273 (1997) H2217-H2223
32. Berry K.L., Skyrme-Jones R.A., and Meredith I.T. Occlusion cuff position is an important determinant of the time course and magnitude of human brachial artery after different circulatory occlusion conditions. Clin Sci 99 (2000) 261-267
33. Naylor L.H., Weisbrod C.J., O'Driscoll G., and Green D.J. Measuring peripheral resistance and conduit arterial structure in humans using Doppler ultrasound. J Appl Physiol 98 (2005) 2311-2315
34. Pyke K.E., and Tschakovsky M.E. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 568 (2005) 357-369
35. Woodman R.J., Playford D.A., Watts G.F., Cheetham C., Reed C., Taylor R.R., et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91 (2001) 929-937
36. Kawano H., Motoyama T., Kugiyama K., Hirashima O., Ohgushi M., Yoshimura M., et al. Menstrual cyclic variation of endothelium-dependent vasodilation of the brachial artery: possible role of estrogen and nitric oxide. Proc Assoc Am Physicians 108 (1996) 473-480
37. Hashimoto M., Akishita M., Eto M., Ishikawa M., Kozaki K., Toba K., et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92 (1995) 3431-3435
38. English J.L., Jacobs L.O., Green G., and Andrews T.C. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol 82 (1998) 256-258
39. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis-a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
40. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85 (1976) 447-452
41. Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 31 (1985) 367-394
42. Hennekens C.H., Evans D.A., Castelli W.P., Taylor J.O., Rosner B., and Kass E.H. Oral contraceptive use and fasting triglyceride, plasma cholesterol and HDL cholesterol. Circulation 60 (1979) 486-489
43. Knopp R.H., Walden C.E., Wahl P.W., Hoover J.J., Warnick G.R., Albers J.J., et al. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. J Clin Endocrin Metab 53 (1981) 1123-1132
44. Nessa A., Latif S.A., and Uddin M. Effects of low dose oral contraceptives on serum total cholesterol, TAG, HDL-C and LDL-C levels in contraceptive users. Mymensingh Med J 14 (2005) 26-28
45. Vogel R.A. Cholesterol lowering and endothelial function. Am J Med 107 (1999) 479-487
46. Vogel R.A., Corretti M.C., and Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiol Dis 41 (1998) 117-136
47. Wilkinson I.B., and Cockcroft J.R. Cholesterol, endothelial function and cardiovascular disease. Curr Opin Lipidol 9 (1998) 237-242
48. Mikkola T., Ranta V., Orpana A., Viinikka L., and Ylikorkala O. Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells. Fertil Steril 66 (1996) 389-393
49. Merki-Feld G.S., Imthurn B., and Keller P.J. The effect of the menstrual cycle and of ethinylestradiol on nitric oxide, endothelin-1 and homocysteine plasma levels. Horm Metabol Res 32 (2000) 288-293
50. Merki-Feld G.S., and Keller P.J. Decrease in endothelin-1 plasma levels during the menstrual cycle and after ethinylestradiol treatment. Ann Intern Med 131 (1999) 394
51. Polderman K.H., Stehouwer C.D., van Kamp G.J., Schalkwijk C.G., and Gooren L.J. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 49 (2000) 648-650
52. Colwell H.H., Mathias S.D., Cimms T.A., Rothman M., Friedman A.J., and Patrick D.L. The ORTHO BC-SAT-a satisfaction questionnaire for women using hormonal contraceptives. Qual Life Res 15 (2006) 1621-1631
53. Roumen F.J.M.E., and Dieben T.O.M. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril 85 (2006) 57-62
54. Sabatini R., and Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 74 (2006) 220-223